Med

NHPC OFS fully subscribed; government raises about ₹4,300 crore

NHPC’s government OFS was fully subscribed on Wednesday, with cumulative bids of 151.33 crore shares against 60.27 crore offered, according to BSE data. The sale raised about ₹4,300 crore. The government planned to sell up to 6% at a ₹71 floor price (8% below ₹77.19 close).

8/10
7/10
Med
OFS final-day subscription results reported today; watch for post-OFS positioning/settlement flows.
Neutral-to-slightly negative given discount floor and dilution framing, offset by full subscription reducing execution risk.

Background

The government is diluting its stake in NHPC via an offer for sale (OFS) with a base 3% and a potential additional 3% green-shoe option, priced with a floor below the prior close.

Why it matters

A fully subscribed OFS at a discount typically affects near-term trading via incremental float and positioning, but successful demand can also cap downside by confirming execution certainty.

Market relevance

Traders may reassess short-term supply overhang and liquidity expectations for NHPC after the OFS cleared with strong bid coverage.

Market effects

Signals continued Indian PSU disinvestment pace, which can influence sentiment toward other state-owned power/utilities via read-across on liquidity and governance narratives.

Primarily India-focused flows as OFS proceeds and investor participation can affect local PSU allocation and index-level liquidity.

Low direct global relevance; mostly domestic capital-markets disinvestment mechanics.

Alternative perspectives

Full subscription suggests demand was strong enough to absorb the discounted supply, so any sell-the-news effect may be limited.

Actual price impact may hinge on settlement timing, whether the green-shoe is exercised fully, and broader PSU/index flow dynamics not covered in the article.

Key entities

  • NHPC

    Indian power PSU subject of the government’s fully subscribed OFS, selling up to 6% stake at a Rs 71 floor.

Related articles

$BCRXMed

BioCryst Pharmaceuticals Backs ORLADEYO Outlook as Navenibart Trial Advances

BioCryst said it expects ORLADEYO to reach $1B peak sales, citing payer mix of ~60% commercial, 20% Medicare Part D and 20% Medicaid and gross-to-net around 15% last year. Pediatric ORLADEYO launch was delayed by a batch manufacturing issue, not safety-related. In Phase 3, navenibart ALPHA-ORBIT enrollment should finish by end-June; top-line data due Q3 next year, with a likely 2H 2028 launch. BioCryst reported pro forma cash of $330M and expects profitability this year and next.

$MUMed

Carnage in chip stocks hits extra hard in top-heavy market

Chip stocks fell sharply as investors weighed higher-rate fears after a strong jobs report and concerns that AI spending may not deliver expected returns. The Nasdaq dropped 4.2% (worst in over a year); Micron, Intel, Super Micro and SanDisk fell 11%+; Nvidia and Cisco fell 6%+. The PHLX Semiconductor Index lost $1.2T, and 2-year Treasury yields rose to 4.16%.

$HDBMed

Why HDFC Mutual Fund has restricted fresh lump sum investments in gold schemes should investors be worried?

HDFC Mutual Fund temporarily restricted fresh lump-sum inflows into its HDFC Gold ETF and HDFC Gold ETF Fund of Fund, citing “broader economic and market conditions.” Direct subscriptions of ₹25 crore+ into the Gold ETF won’t be accepted from June 8, 2026; Gold FoF lump-sum and switch-ins are capped at ₹10 lakh per PAN per month from June 5, 2026. Existing SIPs and exchange trading remain unaffected.

$COINMed

Why Coinbase (COIN) Shares Are Getting Obliterated Today

Coinbase shares fell about 9% in the afternoon after Baird downgraded the stock to a “Bearish Fresh Pick,” cutting its price target to $142 from $160 (Neutral). Baird expects Q2 revenue to miss Wall Street consensus by 5–6%, citing trading activity driven by Bitcoin selling rather than new capital. The move followed a near-6% Bitcoin drop and rate-hike concerns after a strong May jobs report.